In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Modulation of renin-angiotensin-aldosterone system reverses adverse left atrial remodelling in type 2 diabetes

Session Poster session 1

Speaker Thomas Craven

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Systolic and Diastolic Function
  • Session type : Poster Session
  • FP Number : P153

Authors : T Craven (Leeds,GB), E Levelt (Leeds,GB), N Jex (Leeds,GB), M Jain (Leeds,GB), LAE Brown (Leeds,GB), CED Saunderson (Leeds,GB), A Das (Leeds,GB), E Dall' Armellina (Leeds,GB), P Bijsterveld (Leeds,GB), JP Greenwood (Leeds,GB), S Plein (Leeds,GB), PP Swoboda (Leeds,GB)

T Craven1 , E Levelt1 , N Jex2 , M Jain1 , LAE Brown1 , CED Saunderson1 , A Das1 , E Dall' Armellina1 , P Bijsterveld1 , JP Greenwood1 , S Plein1 , PP Swoboda1 , 1University of Leeds - Leeds - United Kingdom of Great Britain & Northern Ireland , 2Leeds Teaching Hospitals NHS Trust - Leeds - United Kingdom of Great Britain & Northern Ireland ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii104

Background: Heart failure is a major cause of morbidity and mortality in type 2 diabetes (T2D). Renin-angiotensin-aldosterone system (RAAS) is a crucial driver of the myocardial structural and functional changes in diabetes.  Left atrial (LA) function recently emerged as an important prognostic factor, thus we aimed to investigate the effect of RAAS inhibition on LA remodelling in T2D patients with microalbuminuria (ACR+). 

Methods: 30 ACR+ T2D patients and 50 ACR- T2D patients were recruited. Patients with prior treatment with insulin or RAAS inhibition were excluded. Cardiac volumes and function were assessed via CMR imaging (3.0T) cine images short axis stack (Figure 1) (10mm LV slices & 5mm LA slices). Following baseline investigations, ACR+ patients were optimised on RAAS inhibition and testing repeated after 1-year. 

Results: ACR + group exhibited significantly worse LA function compared to ACR- group (Table 1). 1-year treatment with RAAS inhibition in the ACR+ group led to significant improvements in LA and LV function, despite no significant changes in 24-hour systolic or diastolic BP (Table 1).

Conclusions: Asymptomatic ACR+ T2D patients exhibit reduced LA function compared to ACR- T2D patients. RAAS inhibition improved LA function, despite no significant change in BP. Supporting mechanisms are likely to include the direct beneficial influence of RAAS inhibition on LA myocardium and given established links between LA function and LV haemodynamics, a decreased LA afterload with reduced LV filling pressures.

ACR -(n=50)

ACR + Baseline (n=30)

P value

ACR + Year 1 (n=30)

P value


62 ± 9 years

63 ± 12 years


Diabetes median duration, years

3 [1.6-6.0]

5 [1.3-6.8]


Mean 24-h BP, mmHg

130 ± 13/

71 ±9

135 ± 19 /

73 ±11


132 ± 20 / 71 ± 11


HbA1c, mmol/L

60 ± 14

61 ± 20


62 ± 16


LV end-diastolic volume, ml




139 ± 37


LV end-systolic volume, ml

58 ±16

60 ± 24


55 ± 25


LV ejection fraction, %

62 ± 5

59 ± 8


62 ±9


LA end systolic volume, ml

89 ± 18

90 ± 30


89 ± 26


LA end diastolic volume, ml

44 ± 11

50 ± 20


46 ±17


LA ejection fraction, %

51 ± 5

45 ± 6


49 ± 6


Table 1: Clinical and imaging parameter differences between ACR- and ACR+ Type 2 Diabetic patients at baseline and ACR+ patients after 1 year of renin-angiotensin-aldosterone system inhibition. ACR, albumin:creatinine ratio; BP, blood pressure; HbA1c, hemoglobin A1c; LA, left atrial; LV, left ventricular; NS, non-significant.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are